<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE- butalbital, acetaminophen, caffeine and codeine phosphate capsule </strong><br>Breckenridge Pharmaceutical, Inc.<br></p></div>
<h1>Butalbital, Acetaminophen, Caffeine, <br>and Codeine Phosphate Capsules <br>CIII</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate is supplied in capsule form for oral administration.</p>
<p>Each capsule contains the following active ingredients:<br><br><br><br></p>
<table width="50%">
<col align="justify" valign="middle" width="80%">
<col align="right" valign="middle" width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="justify">Codeine Phosphate, USP ........................................</td>
<td align="right"> 30 mg</td>
</tr>
<tr>
<td align="justify">Butalbital, USP ........................................................</td>
<td align="right">50 mg</td>
</tr>
<tr>
<td align="justify">Caffeine, USP ......................................................... </td>
<td align="right">40 mg</td>
</tr>
<tr class="Botrule Last">
<td align="justify">Acetaminophen, USP .............................................. </td>
<td align="right">325 mg</td>
</tr>
</tbody>
</table>
<p>Codeine phosphate [7,8-didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1) (salt) hemihydrate, C<span class="Sub">18</span>H<span class="Sub">24</span>N0<span class="Sub">7</span>P, anhydrous mw 397.37], is a narcotic analgesic and antitussive. The structural formula of codeine phosphate is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d74db417-d2de-495b-bb75-46a83745603d&amp;name=butalbital-02.jpg"></div>
<p>Butalbital (5-allyl-5-isobutylbarbituric acid, C<span class="Sub">11</span>H<span class="Sub">16</span>N<span class="Sub">2</span>0<span class="Sub">3</span>, mw 224.26), is a short-to intermediate- acting barbiturate. The structural formula of butalbital is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d74db417-d2de-495b-bb75-46a83745603d&amp;name=butalbital-03.jpg"></div>
<p>Caffeine (1,3,7-trimethylxanthine, C<span class="Sub">8</span>H<span class="Sub">10</span>N<span class="Sub">4</span>O<span class="Sub">2</span>, mw 194.19), is a central nervous system stimulant. The structural formula of caffeine is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d74db417-d2de-495b-bb75-46a83745603d&amp;name=butalbital-04.jpg"></div>
<p>Acetaminophen (4'-hydroxyacetanilide, C<span class="Sub">8</span>H<span class="Sub">9</span>NO<span class="Sub">2</span>, mw 151.16), is a non-opiate, non-salicylate analgesic and antipyretic. The structural formula of acetaminophen is:</p>
<p></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d74db417-d2de-495b-bb75-46a83745603d&amp;name=butalbital-05.jpg"></div>
<p><span class="Italics">Active Ingredients:</span> Codeine Phosphate, USP, Butalbital, USP, Caffeine, USP, and Acetaminophen, USP. <span class="Italics">Inactive Ingredients:</span> FD&amp;C Blue No. 1, FD&amp;C Red No. 3, FD&amp;C Red No. 40, *FD&amp;C Yellow No.5 (see <span class="Bold"><a href="#precau">PRECAUTIONS</a></span>), Gelatin, Microcrystalline Cellulose, Sodium Lauryl Sulfate, Stearic Acid, Talc, Titanium Dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is a combination drug product intended as a treatment for <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span>. Butalbital, Acetaminophen, Caffeine and Codeine Phosphate Capsules consists of a fixed combination of butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg. The role each component plays in the relief of the complex of symptoms known as <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span> is incompletely understood.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The behavior of the individual components is described below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Codeine</h3>
<p class="First">Codeine is readily absorbed from the gastrointestinal tract. It is rapidly distributed from the intravascular spaces to the various body tissues, with preferential uptake by parenchymatous organs such as the liver, spleen and kidney. Codeine crosses the blood-brain barrier, and is found in fetal tissue and breast milk. The plasma concentration does not correlate with brain concentration or relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; however, codeine is not bound to plasma proteins and does not accumulate in body tissues. The plasma half-life is about 2.9 hours. The elimination of codeine is primarily via the kidneys, and about 90% of an oral dose is excreted by the kidneys within 24 hours of dosing. The urinary secretion products consist of free and glucuronide conjugated codeine (about 70%), free and conjugated norcodeine (about 10%), free and conjugated morphine (about 10%), normorphine (about 4%), and hydrocodone (1%). The remainder of the dose is excreted in the feces.</p>
<p>At therapeutic doses, the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> reaches a peak within 2 hours and persists between 4 and 6 hours. See <span class="Bold"><a href="#over">OVERDOSAGE</a></span> for toxicity information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2"></a><p></p>
<h3>Butalbital</h3>
<p class="First">Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and readily cross the placental barrier. They are bound to plasma and tissue proteins to a varying degree and binding increases directly as a function of lipid solubility.</p>
<p>Elimination of butalbital is primarily via the kidney (59% to 88% of the dose) as unchanged drug or metabolites. The plasma half-life is about 35 hours. Urinary excretion products include parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8% of the dose), products with the barbituric acid ring hydrolyzed with excretion of urea (about 14% of the dose), as well as unidentified materials. Of the material excreted in the urine, 32% is conjugated.</p>
<p>The <span class="Italics">in vitro</span> plasma protein binding of butalbital is 45% over the concentration range of 0.5 to 20 mcg/mL. This <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> within the range of plasma protein binding (20% to 45%) reported with other barbiturates such as phenobarbital, pentobarbital, and secobarbital sodium. The plasma-to-blood concentration ratio was almost unity indicating that there is no preferential distribution of butalbital into either plasma or blood cells. See <span class="Bold"><a href="#over">OVERDOSAGE</a></span> for toxicity information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>Caffeine</h3>
<p class="First">Like most xanthines, caffeine is rapidly absorbed and distributed in all body tissues and fluids, including the CNS, fetal tissues, and breast milk. Caffeine is cleared through metabolism and excretion in the urine. The plasma half-life is about 3 hours. Hepatic biotransformation prior to excretion results in about equal amounts of 1-methylxanthine and 1-methyluric acid. Of the 70% of the dose that is recovered in the urine, only 3% is unchanged drug. See <span class="Bold"><a href="#over">OVERDOSAGE</a></span> for toxicity information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4"></a><p></p>
<h3>Acetaminophen</h3>
<p class="First">Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug. See <span class="Bold"><a href="#over">OVERDOSAGE</a></span> for toxicity information.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the relief of the symptom complex of <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> (or muscle contraction) <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Evidence supporting the efficacy and safety of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules in the treatment of multiple recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This combination product is contraindicated under the following conditions:</p>
<p>- <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or intolerance to acetaminophen, caffeine, butalbital, or codeine.</p>
<p>- Patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> or other intracranial lesions, the respiratory depressant effects of codeine and other narcotics may be markedly enhanced, as well as their capacity for elevating cerebrospinal fluid pressure. Narcotics also produce other CNS depressant effects, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, that may further obscure the clinical course of the patients with head injuries.</p>
<p>Codeine or other narcotics may obscure signs on which to judge the diagnosis or clinical course of patients with acute abdominal conditions. Butalbital and codeine are both habit-forming and potentially abusable.</p>
<p>Consequently, the extended use of this combination product is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precau"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules should be prescribed with caution in certain special-risk patients such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, head injuries, elevated intracranial pressure, acute abdominal conditions, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, Addison's disease, or <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ultra"></a><a name="section-7.2"></a><p></p>
<h2>Ultra-rapid Metabolizers of Codeine</h2>
<p class="First">Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1-10% in Caucasians, 3% in African Americans, and 16-28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.</p>
<p>When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and should inform their patients about these risks and the signs of morphine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. (See <span class="Bold"><a href="#nursing">PRECAUTIONS, Nursing Mothers</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>FD&amp;C Yellow No. 5 (Tartrazine)</h2>
<p class="First">This product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible persons. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this combination product. Alcohol and other CNS depressants may produce an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> when taken with this combination product and should be avoided. Codeine and butalbital may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed. For information on use in geriatric patients, see <span class="Bold"><a href="#geriatric">PRECAUTIONS/Geriatric Use</a></span>.</p>
<p>Caution patients that some people have a variation in a liver enzyme and change codeine into morphine more rapidly and completely than other people. These people are ultra-rapid metabolizers and are more likely to have higher-than-normal levels of morphine in their blood after taking codeine which can result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. In most cases, it is unknown if someone is an ultra-rapid codeine metabolizer.</p>
<p>Nursing mothers taking codeine can also have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Instruct nursing mothers to watch for signs of morphine toxicity in their infants including increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the baby's doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.5"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In patients with severe hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, effects of therapy should be monitored with serial liver and/or renal function tests.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules may enhance the effects of:</p>
<p>- Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.7"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1"></a><p></p>
<h3>Codeine</h3>
<p class="First">Codeine may increase serum amylase levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.2"></a><p></p>
<h3>Acetaminophen</h3>
<p class="First">Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.8"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine whether acetaminophen, codeine and butalbital have a potential for carcinogenesis or mutagenesis. No adequate studies have been conducted in animals to determine whether acetaminophen and butalbital have a potential for impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.9"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.9.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.9.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies have not been conducted with Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules. It is also not known whether Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This combination product should be given to a pregnant woman only when clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.9.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal seizures</span> were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last 2 months of pregnancy. Butalbital was found in the infant's serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or other withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.10"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Use of codeine during labor may lead to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="nursing"></a><a name="section-7.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Caffeine, barbiturates, acetaminophen and codeine are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of potential for serious adverse reactions in nursing infants from Butalbital, Acetaminophen, Caffeine and Codeine Phosphate Capsules, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. Despite the common use of codeine products to manage postpartum <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, reports of adverse events in infants are rare. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine's active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in nursing infants.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1-10% in Caucasians, 3% in African Americans, and 16-28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.</p>
<p>The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding. (See <span class="Bold"><a href="#ultra">PRECAUTIONS, General, Ultra-rapid Metabolizers of Codeine</a></span>)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.12"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="geriatric"></a><a name="section-7.13"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Butalbital is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Frequently Observed:</span> The most frequently reported adverse reactions are <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and intoxicated feeling.</p>
<p><span class="Bold">Infrequently Observed:</span> All adverse events tabulated below are classified as infrequent.</p>
<p><span class="Bold">Central Nervous:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, shaky feeling, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, heavy eyelids, high energy, hot spells, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">sluggishness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Mental confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> can also occur due to intolerance, particularly in elderly or debilitated patients, or due to overdosage of butalbital.</p>
<p><span class="Bold">Autonomic Nervous:</span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> difficulty swallowing, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Bold">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>.</p>
<p><span class="Bold">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</p>
<p><span class="Bold">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<p><span class="Bold">The following adverse reactions have been voluntarily reported as temporally associated with Fiorinal<span class="Sup">®</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a> with Codeine, a related product containing aspirin, butalbital, caffeine, and codeine phosphate.</span></p>
<p><span class="Bold">Central Nervous:</span> abuse, addiction, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, libido decrease, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, sexual activity increase, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Bold">Autonomic Nervous:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, appetite increased, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, gastrointestinal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, mouth burning, <span class="product-label-link" type="condition" conceptid="4189591" conceptname="Pyloric ulcer">pyloric ulcer</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, hypotensive reaction, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold">Skin:</span> <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
<p><span class="Bold">Urinary:</span> kidney impairment, urinary difficulty.</p>
<p><span class="Bold">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="4321680" conceptname="Cholangiocarcinoma">cholangiocarcinoma</span>, drug interaction with erythromycin (<span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span>), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p><span class="Bold">The following adverse drug events may be borne in mind as potential effects of the components of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules. Potential effects of high dosage are listed in the <a href="#over">OVERDOSAGE</a> section.</span></p>
<p><span class="Bold">Acetaminophen:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p><span class="Bold">Caffeine:</span> cardiac stimulation, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="Bold">Codeine:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. Several cases of dermatological reactions, including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, have been reported for Butalbital, Acetaminophen, Caffeine and Codeine Phosphate Capsules, USP.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Fiorinal<span class="Sup">®</span> is a registered trademark of Watson Pharmaceuticals, Inc.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34085-1">
<a name="section-9.1"></a><p></p>
<h2>Controlled Substance</h2>
<p class="First">Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is controlled by the Drug Enforcement Administration and is classified under Schedule III.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="section-9.2"></a><p></p>
<h2>Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.1"></a><p></p>
<h3>Codeine</h3>
<p class="First">Codeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and, therefore, has the potential for being abused. Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic medications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.2"></a><p></p>
<h3>Butalbital</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.2.1"></a><p></p>
<h4>Barbiturates may be habit-forming</h4>
<p class="First">Tolerance, psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1,500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> consists of cautious and gradual withdrawal of the drug.</p>
<p>Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="over"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, toxicity may result from the barbiturate, the codeine, or the acetaminophen. Toxicity due to the caffeine is less likely, due to the relatively small amounts in this formulation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Toxicity from <span class="Bold Italics">barbiturate</span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> includes <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; and <span class="product-label-link" type="condition" conceptid="4192647" conceptname="Hypovolemic shock">hypovolemic shock</span>. Toxicity from <span class="Bold Italics">codeine</span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> includes the opioid triad of: pinpoint pupils, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration, and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may occur. In <span class="Bold Italics">acetaminophen</span> overdosage : dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. Renal tubular necroses, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may also occur. Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. In adults hepatic toxicity has rarely been reported with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span> of less than 10 grams, or fatalities with less than 15 grams. Acute <span class="Bold Italics">caffeine</span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may cause <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">A single or multiple <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> should be induced mechanically, or with syrup of ipecac, if the patient is alert (adequate pharyngeal and laryngeal reflexes). Oral activated charcoal (1 g/kg) should follow gastric emptying. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as required. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> is usually hypovolemic and should respond to fluids. The value of vasopressor agents such as norepinephrine or phenylephrine hydrochloride in treating <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is questionable since they increase <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> and decrease blood flow. However, if prolonged support of blood pressure is required, norepinephrine bitartrate (Levophed<span class="Sup">®</span>)<a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a> may be given I.V. with the usual precautions and serial blood pressure monitoring. A cuffed endotracheal tube should be inserted before gastric lavage of the <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> patient and, when necessary, to provide assisted respiration. If renal function is normal, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> may aid in the elimination of the barbiturate. Alkalinization of the urine increases renal excretion of some barbiturates, especially phenobarbital.</p>
<p>Meticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, peritoneal dialysis, or preferably hemodialysis may be considered. If <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> occurs due to acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, vitamin K should be administered intravenously.</p>
<p>Naloxone, a narcotic antagonist, can reverse <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> associated with opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Naloxone 0.4 to 2 mg is given parenterally. Since the duration of action of codeine may exceed that of the naloxone, the patient should be kept under continuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>If the dose of acetaminophen may have exceeded 140 mg/kg, N-acetyl-cysteine should be administered as early as possible. Serum acetaminophen levels should be obtained, since levels 4 or more hours following ingestion help predict acetaminophen toxicity. Do not await acetaminophen assay results before initiating treatment. Hepatic enzymes should be obtained initially, and repeated at 24-hour intervals. <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> over 30% should be treated with methylene blue by slow intravenous administration.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>Levophed<span class="Sup">®</span> is a registered Trademark of Hospira, Inc.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Toxic doses (for adults)</h2>
<p class="First"><span class="Bold">Butalbital:</span> toxic dose 1 g (20 capsules)</p>
<p><span class="Bold">Acetaminophen:</span> toxic dose 10 g (30 capsules)</p>
<p><span class="Bold">Caffeine:</span> toxic dose 1 g (25 capsules)</p>
<p><span class="Bold">Codeine:</span> toxic dose 240 mg (8 capsules).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">One or two capsules every four hours. Total daily dosage should not exceed six capsules.</p>
<p>Extended and repeated use of this combination product is not recommended because of the potential for physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules:</span> Dark blue, opaque cap with a gray, opaque body, and body is imprinted with "B 073" in black ink.</p>
<p>Bottles of 100's (NDC 51991-073-01)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2>Store and Dispense</h2>
<p class="First">Store at 20° to 25°C (68° to 77°F) in a tight, light-resistant container. [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:<br>Nexgen Pharma, Inc.<br>Irvine, CA 92614</p>
<p>Distributed by:<br>Breckenridge Pharmaceutical, Inc.<br>Boca Raton, FL 33847</p>
<p>6670(Rev. 10/08)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 Capsule Bottle</h1>
<p class="First"><span class="Bold">Breckenridge<br>Pharmaceutical, Inc.</span></p>
<p><span class="Bold">NDC 51991-073-01</span></p>
<p><span class="Bold">Butalbital, Acetaminophen,<br>Caffeine, and Codeine <br>Phosphate Capsules <br>CIII</span></p>
<table width="50%">
<col align="justify" valign="middle" width="80%">
<col align="right" valign="middle" width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="justify">Codeine Phosphate, USP ........................................</td>
<td align="right"> 30 mg</td>
</tr>
<tr>
<td align="justify">Butalbital, USP ........................................................</td>
<td align="right">50 mg</td>
</tr>
<tr>
<td align="justify">Caffeine, USP ......................................................... </td>
<td align="right">40 mg</td>
</tr>
<tr class="Botrule Last">
<td align="justify">Acetaminophen, USP .............................................. </td>
<td align="right">325 mg</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Rx Only <br>100 Capsules</span></p>
<div class="Figure"><img alt="Principal Display Panel - 100 Capsule Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d74db417-d2de-495b-bb75-46a83745603d&amp;name=butalbital-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE 		
					</strong><br><span class="contentTableReg">butalbital, acetaminophen, caffeine and codeine phosphate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51991-073</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Butalbital</strong> (Butalbital) </td>
<td class="formItem">Butalbital</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Acetaminophen</strong> (Acetaminophen) </td>
<td class="formItem">Acetaminophen</td>
<td class="formItem">325 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Caffeine</strong> (Caffeine) </td>
<td class="formItem">Caffeine</td>
<td class="formItem">40 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Codeine Phosphate</strong> (Codeine) </td>
<td class="formItem">Codeine</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Red No. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Yellow No. 5</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Cellulose, Microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Lauryl Sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Stearic Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Titanium Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE, GRAY</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">B073</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51991-073-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076560</td>
<td class="formItem">07/01/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Breckenridge Pharmaceutical, Inc.
							(150554335)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nexgen Pharma</td>
<td class="formItem"></td>
<td class="formItem">048488621</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2d433ed3-4376-4849-8943-d832cfd73462</div>
<div>Set id: d74db417-d2de-495b-bb75-46a83745603d</div>
<div>Version: 2</div>
<div>Effective Time: 20091020</div>
</div>
</div> <div class="DistributorName">Breckenridge Pharmaceutical, Inc.</div></p>
</body></html>
